drugset / Trial / NCT01984268

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

NCT01984268

RandomizedParallel-groupSingle-blindTreatment

Summary

Adenocorticotrophic Hormone provides safe and effective treatment to induce disease remission in rheumatoid arthritis patients with active disease due to an inadequate response to methotrexate.

Timeline

Start
2014-06-23
Primary completion
2016-09-01
Completion
2016-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide

Indications